Voya Investment Management LLC Buys 10,878 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Voya Investment Management LLC increased its stake in Kiniksa Pharmaceuticals by 54.4%, acquiring an additional 10,878 shares, bringing its total to 30,866 shares valued at approximately $686,000.
• Several institutional investors have shown interest in Kiniksa, with 53.95% of the company's stock now held by institutional investors, including new positions taken by firms like US Bancorp and Asset Management One.
• Kiniksa Pharmaceuticals reported a $0.23 EPS for the last quarter, exceeding analyst expectations of $0.18, alongside a revenue of $156.80 million, which also surpassed estimates.

Voya Investment Management LLC raised its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 54.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 30,866 shares of the company's stock after purchasing an additional 10,878 shares during the period. Voya Investment Management LLC's holdings in Kiniksa Pharmaceuticals International were worth $686,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of KNSA. GAMMA Investing LLC raised its position in Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the last quarter. US Bancorp DE bought a new position in Kiniksa Pharmaceuticals International during the 1st quarter worth $33,000. Asset Management One Co. Ltd. bought a new position in Kiniksa Pharmaceuticals International during the 1st quarter worth $41,000. Wealthquest Corp bought a new position in Kiniksa Pharmaceuticals International during the 1st quarter worth $42,000. Finally, Fox Run Management L.L.C. bought a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth about $252,000. 53.95% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

KNSA has been the subject of several research analyst reports. Jefferies Financial Group lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Wells Fargo & Company lifted their price objective on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an "overweight" rating in a research report on Thursday. Wedbush reissued an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Finally, Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 7th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $41.67.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $35.51 on Friday. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $37.34. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of 887.97 and a beta of 0.20. The business has a 50-day simple moving average of $33.22 and a 200 day simple moving average of $28.01.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, COO Eben Tessari sold 16,400 shares of the business's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $36.46, for a total value of $597,944.00. Following the completion of the sale, the chief operating officer directly owned 34,552 shares of the company's stock, valued at $1,259,765.92. The trade was a 32.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Thomas Malley sold 78,233 shares of the business's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the sale, the director directly owned 12,546 shares of the company's stock, valued at $415,147.14. The trade was a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 561,371 shares of company stock valued at $18,825,009. 53.48% of the stock is currently owned by corporate insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.